494 related articles for article (PubMed ID: 11786932)
21. Overexpression of cell division cycle 7 homolog is associated with gene amplification frequency in breast cancer.
Choschzick M; Lebeau A; Marx AH; Tharun L; Terracciano L; Heilenkötter U; Jaenicke F; Bokemeyer C; Simon R; Sauter G; Schwarz J
Hum Pathol; 2010 Mar; 41(3):358-65. PubMed ID: 19896697
[TBL] [Abstract][Full Text] [Related]
22. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
Wärnberg F; Nordgren H; Bergkvist L; Holmberg L
Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839
[TBL] [Abstract][Full Text] [Related]
23. c-myc amplifications in primary breast carcinomas and their local recurrences.
Aulmann S; Adler N; Rom J; Helmchen B; Schirmacher P; Sinn HP
J Clin Pathol; 2006 Apr; 59(4):424-8. PubMed ID: 16497871
[TBL] [Abstract][Full Text] [Related]
24. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
Half E; Tang XM; Gwyn K; Sahin A; Wathen K; Sinicrope FA
Cancer Res; 2002 Mar; 62(6):1676-81. PubMed ID: 11912139
[TBL] [Abstract][Full Text] [Related]
25. Abnormal FHIT gene transcript and c-myc and c-erbB2 amplification in breast cancer.
Kowara R; Gołebiowski F; Chrzan P; Skokowski J; Karmolinski A; Pawełczyk T
Acta Biochim Pol; 2002; 49(2):341-50. PubMed ID: 12362975
[TBL] [Abstract][Full Text] [Related]
26. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
27. Breast carcinogenesis. Transition from hyperplasia to invasive lesions.
Meteoglu I; Dikicioglu E; Erkus M; Culhaci N; Kacar F; Ozkara E; Uyar M
Saudi Med J; 2005 Dec; 26(12):1889-96. PubMed ID: 16380768
[TBL] [Abstract][Full Text] [Related]
28. p53 mutations and histological type of invasive breast carcinoma.
Marchetti A; Buttitta F; Pellegrini S; Campani D; Diella F; Cecchetti D; Callahan R; Bistocchi M
Cancer Res; 1993 Oct; 53(19):4665-9. PubMed ID: 8402644
[TBL] [Abstract][Full Text] [Related]
29. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
30. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer.
Berns EM; Klijn JG; van Putten WL; van Staveren IL; Portengen H; Foekens JA
Cancer Res; 1992 Mar; 52(5):1107-13. PubMed ID: 1737370
[TBL] [Abstract][Full Text] [Related]
31. The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast.
Liu E; Thor A; He M; Barcos M; Ljung BM; Benz C
Oncogene; 1992 May; 7(5):1027-32. PubMed ID: 1349163
[TBL] [Abstract][Full Text] [Related]
32. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations.
Gaffey MJ; Frierson HF; Williams ME
Mod Pathol; 1993 Nov; 6(6):654-9. PubMed ID: 7905628
[TBL] [Abstract][Full Text] [Related]
33. [Invasive ductal carcinoma of the breast: study of the number of copies of the CCND1 gene and chromosome 11 using fluorescence in situ hybridization (FISH) in comparison with expression of cyclin D1 protein and estrogen receptors (ER alpha) with immunohistochemical detection].
Mrhalová M; Kodet R; Strnad P
Cas Lek Cesk; 2002 Nov; 141(22):708-14. PubMed ID: 12532908
[TBL] [Abstract][Full Text] [Related]
34. Angiogenic potential of ductal carcinoma in situ (DCIS) of human breast.
Vogl G; Dietze O; Hauser-Kronberger C
Histopathology; 2005 Dec; 47(6):617-24. PubMed ID: 16324200
[TBL] [Abstract][Full Text] [Related]
35. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.
Bijker N; Peterse JL; Duchateau L; Robanus-Maandag EC; Bosch CA; Duval C; Pilotti S; van de Vijver MJ
Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051
[TBL] [Abstract][Full Text] [Related]
36. Chromosomal alterations associated with the transition from in situ to invasive breast cancer.
Ellsworth RE; Vertrees A; Love B; Hooke JA; Ellsworth DL; Shriver CD
Ann Surg Oncol; 2008 Sep; 15(9):2519-25. PubMed ID: 18622645
[TBL] [Abstract][Full Text] [Related]
37. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.
Emberley ED; Alowami S; Snell L; Murphy LC; Watson PH
Breast Cancer Res; 2004; 6(4):R308-15. PubMed ID: 15217497
[TBL] [Abstract][Full Text] [Related]
38. Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array.
Rummukainen JK; Salminen T; Lundin J; Kytölä S; Joensuu H; Isola JJ
Mod Pathol; 2001 Oct; 14(10):1030-5. PubMed ID: 11598174
[TBL] [Abstract][Full Text] [Related]
39. Alteration of cyclin D1 in Chinese patients with breast carcinoma and its correlation with Ki-67, pRb, and p53.
Guo LL; Gao P; Wu YG; Jian WC; Hao CY; Li H; Lin XY
Arch Med Res; 2007 Nov; 38(8):846-52. PubMed ID: 17923265
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome.
Krüger S; Weitsch G; Büttner H; Matthiensen A; Böhmer T; Marquardt T; Sayk F; Feller AC; Böhle A
Int J Oncol; 2002 Nov; 21(5):981-7. PubMed ID: 12370744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
